Vivos Therapeutics, Inc. (VVOS) To Buy 11% of SOD Sciences, 50% of Pseudohypoxia Test IP via $12M Preferred

Vivos Therapeutics (VVOS) agreed to buy 11% of SOD Sciences and 50% of its pseudohypoxia test IP for $12M in Series C Convertible Preferred Stock. The deal is expected to close by October 15, 2026, pending conditions. VVOS aims to strengthen its equity and revenue streams as part of its Nasdaq compliance efforts.

Original reporting
Published Oct 15, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vivos Therapeutics, Inc. (VVOS) To Buy 11% of SOD Sciences, 50% of Pseudohypoxia Test IP via $12M Preferred — source image
Decision brief

The 30-second read

$VVOSBullishMed
01

Why it matters

The acquisition could diversify Vivos' revenue base if the pseudohypoxia test achieves clinical validation, but the $12M valuation suggests modest immediate impact.

02

Market read

A small‑cap M&A announcement that may provide incremental upside for Vivos but is unlikely to drive significant market movement.

03

What to watch

Potential regulatory or clinical validation hurdles for the pseudohypoxia test could delay revenue generation.

Relevance 6/10Novelty 6/10Timing: today

Background

Vivos Therapeutics is seeking to strengthen its pipeline and meet Nasdaq compliance through strategic, non‑cash deals.

Company-level read

Ticker impact

$VVOSBullishMedium confidence
Context

Vivos Therapeutics announced a definitive agreement to purchase an 11% stake in SOD Sciences and 50% of related IP for $12M of Series C Convertible Preferred Stock.

Expected impact

limited upside as the market prices in the strategic acquisition, but no strong directional pressure.

Evidence & confidence

First‑report of a small‑cap M&A transaction; the amount is modest and the closing is conditional, so price reaction is likely muted.

Market effects

Adds a modest strategic partnership in the biotech/diagnostics space, but unlikely to shift sector dynamics.

Primarily affects US micro‑cap market; no broader regional effect.

Limited to Vivos shareholders and niche investors.

Counterpoint

The small size and conditional closing may mean the deal will not materialize, limiting upside.

Key entities

  • Vivos Therapeutics, Inc.

    US‑listed biotech firm executing the acquisition.

  • SOD Sciences

    Target of the 11% equity stake and IP co‑ownership.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$DASHHighAI 9/10

DoJ To Reportedly Scrutinize DoorDash And Instacart’s $17B Merger

The U.S. Department of Justice will review DoorDash's proposed $17 billion acquisition of Instacart, valued at $65 per share, according to Reuters. The deal aims to expand DoorDash's presence in the U.S. online grocery market. DASH stock rose 0.7% after-hours, while CART stock fell $2. The transaction is expected to close by late 2027 or early 2028, pending regulatory approval.